LFCR - Lifecore Biomedical - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LFCR is currently covered by 3 analysts with an average price target of $9.35. This is a potential upside of $2.13 (29.5%) from yesterday's end of day stock price of $7.22.

Lifecore Biomedical's activity chart (see below) currently has 8 price targets and 11 ratings on display. The stock rating distribution of LFCR is 42.86% BUY and 57.14% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 60% with an average time for these price targets to be met of 102 days.

Highest price target for LFCR is $8, Lowest price target is $4.

Most recent stock forecast was given by MICHAEL PETUSKY from BARRINGTON on 28-Aug-2024. First documented stock forecast 11-Jan-2023.

Best performing analysts who are covering LFCR - Lifecore Biomedical:

Michael Petusky

Currently out of the existing stock ratings of LFCR, 3 are a BUY (42.86%), 4 are a HOLD (57.14%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Michael Petusky (BARRINGTON)

Hold

$10

11 months 15 days ago
(28-Aug-2024)

3/5 (60%)

$2.13 (27.06%)

102

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is LFCR (Lifecore Biomedical) average time for price targets to be met?

On average it took 102 days on average for the stock forecasts to be realized with a an average price target met ratio 60

Which analyst has the current highest performing score on LFCR (Lifecore Biomedical) with a proven track record?

MICHAEL PETUSKY

Which analyst has the most public recommendations on LFCR (Lifecore Biomedical)?

Michael Petusky works at BARRINGTON and has 40 price targets and 27 ratings on LFCR

Which analyst is the currently most bullish on LFCR (Lifecore Biomedical)?

Michael Petusky with highest potential upside - $0

Lifecore Biomedical in the News

Lifecore (LFCR) Q4 Revenue Beats 3%

Key Points GAAP revenue exceeded expectations at $36.4 million in Q4 FY2025, Revenue beat analyst estimates by 2.76% (GAAP), despite a year-over-year decline. GAAP earnings per share showed a narrower loss of $(0.06) in Q4 FY2025, outperforming the estimated $(0.10) GAAP loss. Gross profit (GAAP) and adjusted EBITDA (non-GAAP) decreased year over year.These 10 stocks...

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

— Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook — — Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company’s Traditional Area of Strength in Ophthalmic Therapeutics — — Improved Efficiency and Productivity Across the Organization — Conference Call Today...